|
|||||
|
|
Homocysteine pre-treatment increases redox capacity in both endothelial and tumor cells |
|
| Authors: | Elena Díaz-Santiago Luis Rodríguez-Caso Casimiro Cárdenas José J Serrano Ana R Quesada |
| Institution: | 1. Departamento de Biología Molecular y Bioquímica, Facultad de Ciencias, and IBIMA (Biomedical Research Institute of Málaga), Universidad de Málaga, Andalucía Tech, Spain;2. Research Support Central Services (SCAI) of the University of Málaga, Spain;3. CIBER de Enfermedades Raras (CIBERER), E-29071 Málaga, Spain |
| Abstract: | Objective: We studied the modulatory effects of homocysteine pre-treatment on the disulfide reduction capacity of tumor and endothelial cells. Methods: Human MDA-MB-231 breast carcinoma and bovine aorta endothelial cells were pre-treated for 1–24 hours with 0.5–5 mM homocysteine or homocysteine thiolactone. After washing to eliminate any rest of homocysteine or homocysteine thiolactone, cell redox capacity was determined by using a method for measuring disulfide reduction. Results: Homocysteine pre-treatments for 1–4 hours at a concentration of 0.5–5 mM increase the disulfide reduction capacity of both tumor and endothelial cells. This effect cannot be fully mimicked by either cysteine or homocysteine thiolactone pre-treatments of tumor cells. Discussion: Taken together, our data suggest that homocysteine can behave as an anti-oxidant agent by increasing the anti-oxidant capacity of tumor and endothelial cells. |
| Keywords: | MDA-MB231 breast cancer cell Bovine aortic endothelial cells Homocysteine Homocysteine thiolactone Cysteine Redox |